

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
27 October 2005 (27.10.2005)

PCT

(10) International Publication Number
WO 2005/100325 A1

(51) International Patent Classification⁷: **C07D 241/04**,
207/04, 205/04, 211/06, 265/30, C07C 237/20, A61K
31/165, 31/495, 31/40, 31/397, 31/445, 31/5375, A61P
25/00, 9/00, 1/00

(21) International Application Number:
PCT/SE2005/000501

(22) International Filing Date: 6 April 2005 (06.04.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0400969-2 14 April 2004 (14.04.2004) SE
0400967-6 14 April 2004 (14.04.2004) SE

(71) Applicant (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BERNSTEIN, Peter** [US/US]; AstraZeneca Wilmington, P.O. Box 15437, Wilmington, DE 19850-5437 (US). **DANTZMAN, Cathy** [US/US]; AstraZeneca Wilmington, P.O. Box 15437, Wilmington, DE 19850-5437 (US). **PALMER, William** [US/US]; AstraZeneca Wilmington, P.O. Box 15437, Wilmington, DE 19850-5437 (US).

(74) Agent: **ASTRAZENECA**; Global Intellectual Property, S-151 85 Södertälje (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **ARYL GLYCINAMIDE DERIVATIVES AND THEIR USE AS NK1 ANTAGONISTS AND SEROTONIN REUPTAKE INHIBITORS**



are neurokinin 1 (NK₁) receptor antagonists and/or serotonin reuptake inhibitors, with medical indications for depression, anxiety disorders and other conditions.

(57) Abstract: Compounds of the following Formula (I) wherein R¹ and R² are independently selected from alkyl or alkenyl or from a heterocyclic ring together with the N to which they are bound, n is 0-2, Ar¹ is (substituted) phenyl and Ar² is (substituted) phenyl, naphthyl or tetralin, further as defined in the specification, in vivo-hydrolysable precursors and pharmaceutically acceptable salts thereof, the use in therapy and pharmaceutical compositions and methods of treatment using the same. The compounds



WO 2005/100325 A1